Imatinib

Where the papers sit

9 papers from the last 6 months study imatinib directly · updated from PubMed 13 Oct 2026

• Chronic Myeloid Leukemia Resistance

  Chronic myeloid leukemia work is moving beyond imatinib response rates toward resistance mechanisms, treatment outcomes, and TKI-associated vascular effects. circ_0029325 is linked to resistance through the CDCA4/AKT axis, while cohort studies compare pediatric treatment patterns and nilotinib-era outcomes. Arterial stiffness highlights a recurring concern with long-term TKI therapy. Imatinib hybrids and NCX1-targeted approaches remain exploratory routes to new therapies.

  5 papers · 55.6%

• Others — GIST and Vascular Calcification

  Ultrasound-responsive PLGA nanoparticles are being used to co-deliver celecoxib and catalase, improving imatinib activity against gastrointestinal stromal tumors. The other study examines platelet-derived growth factor in uremic vascular calcification. These topics share no biological question, treatment strategy, or endpoint. No common direction can therefore be assigned.

  2 papers · 22.2%

• Others — Sarcoma and Tuberculous Meningitis

  Targeted small molecules are being evaluated in Ewing sarcoma and desmoplastic small round cell tumor models, including entinostat and compounds affecting TP53 or PMAIP1-linked biology. A separate line develops host-directed treatments for tuberculous meningitis across mouse and human systems. The studies do not share a disease mechanism, therapeutic rationale, or outcome. No unified treatment direction emerges from this grouping.

  2 papers · 22.2%